All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 25, 2021
Home » Blogs » BioWorld Perspectives » Biotech Dating, Marriage, Divorce . . . and the New Alternatives

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Biotech Dating, Marriage, Divorce . . . and the New Alternatives

April 14, 2011
By Lynn Yoffee
No Comments

Marriage is both heaven and hell. So it goes with people and so it goes with biotech firms racing to bring new drugs to market. Faced with up to $1 billion to bring a drug from idea to patient, funding more than a decade of work is a complicated affair, especially amid these weak market conditions.

Just as people enter courtships and marriages with different hopes and long-term game plans, biotechs hope for long honeymoons, but are smacked with real-life challenges.

BioWorld Today relays news of countless deals gone sour, mostly when drugs don’t pass muster. But sometimes it’s because the deal wasn’t properly vetted. Our Washington editor, Mari Serebrov, recently wrote an article for BioWorld Insight on the horror stories of how firms spend millions and billions of dollars only to find out that their new partner didn’t have clear ownership of the intellectual property. “The problem is too many companies aren’t learning that lesson before they walk down the aisle,” Serebrov wrote. “Pressed by competition from other suitors, the bottom line and the fast pace of dealmaking, they forget that beauty, even in business deals, may be only skin deep.”

Fearful of matrimony (or just unable to land a date), some biotechs go solo. But faced with a lack of traditional financing options these days, these biotech bachelors and bachelorettes increasingly are turning to an “alternative financing bag of tricks,” as BioWorld Assistant Managing Editor Jennifer Boggs wrote recently in BioWorld Insight. These range from rights offerings and selling royalty streams to grants and at-the-market offerings. But none of these options draw enough money to fund costly R&D programs for long, with a series of fundraisings that must ensue over and over again.

Little start-up Nimbus Discovery LLC (with a computational drug discovery model that attracted heavyweight investor Bill Gates, of Microsoft fame) however, might be on to one of the best new models to stay funded . . . multiple partners. That may not be so Kosher among many cultures for people (shades of Big Love or Sister Wives?), but it could be the true answer for savvy biotechs. Rather than banking successive investments from various sources on a decade-long hope for a successful exit, Nimbus is placing its three programs each into separate units, gambling that it will have a better chance of being able to monetize each one as a standalone.

What’s different about the Nimbus strategy? In fact, a lot of firms have multiple partners –Seattle Genetics has a dozen deals involving its platform technologies and other firms have multiple deals for a single product across different regional areas. Nimbus’ strategy is focused on M&A. By operating as a holding company, they’re hoping to attract a big pharma to buy those single-asset entities. That way, Nimbus gets to divest a product early after Phase I or so without having to convince big pharma to buy the whole shebang.

Divide and conquer? Don’t put all your eggs in one basket? Can I think of one more lame saying? You get the idea. We’ll see how it goes for Nimbus over the long haul. Diversification makes sense for personal investments – why not fledgling biotechs too? Most people, however, might not be so amenable to plural marriage, despite the drama and reality shows of late.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 25.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing